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S198 Poster Session Icell (pCD34) count of\10/mL after 4 days of F alone. In this studywe
present the results of efficacy and an estimate of cost of such a risk
adaptive strategy for autologous peripheral blood HPC collection.
42 patients with history of NHL orMMundergoing peripheral blood
HPCmobilization fromFebruary toDecember 2009were included in
the analysis. All patients received daily filgrastim for 4 days. Our risk
adaptive approach was to add P for those ‘at-risk’ patients, who on day
4 had a pCD34 count of\10/mL,with apheresis commencing the fol-
lowing morning. Morning administration of F and evening dosing of
Pwas continued daily in this group of ‘at-risk’ patients for up to amax-
imum of 4 days or until. 5 106 CD341 cells/kgwere collected. Re-
sults of consecutive patients who had peripheral blood HPC
mobilization were prospectively collected. A decision analytic model
was created to estimate the mean cost and effectiveness rates in pa-
tients who underwent mobilization with F versus F 1 P. 18 patients
were mobilized with F alone and 24 patients required F1 P. Admin-
istration of P was safe and no severe adverse events were recorded. Ad-
dition of P increased the pCD34 count by 6.8 fold with an average
total yield of 4.9  106 CD341 cells/kg. The frequency of poor mo-
bilization among F only and F1 P patients was 25% and 7% respec-
tively. The pooled average cost benefit for mobilization with F 1 P
may be up to $ 16,900 per patient and could potentially increase the
annual number of transplants by more than 18%. Following autolo-
gous stem cell infusion, days to neutrophil and platelet engraftments
were similar between the patients who mobilized HPC with F versus
F 1 P (p5 0.12). These results suggest that addition of P to F based
on a risk adaptive strategy significantly reduces the frequency of mo-
bilization failures and is also cost effective. Addition of P to F forHPC
mobilization has no significant impact on the neutrophil and platelet
engraftment.121
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Background: NE is an acute, life-threatening condition character-
ized by transmural inflammation of the intestinal wall in severely
myelosuppressed patients. Although initially described in pediatric
leukemia pts it has increasingly been reported in adults with a variety
of malignant conditions and in the setting of immunosuppression
with HSCT. The aim of this retrospective study was to evaluate
the prognostic value of clinical and radiographic findings in HSCT
recipients diagnosed with NE.
Patients and Methods: Data from 264 HSCT recipients over a 5
year period was reviewed. 24 pts with a clinical diagnosis of NE
supported by the triad of fever, abdominal pain and neutropenia
with radiographic evidence of bowel wall thickening (BWT) were
identified. Degree of BWT by CT scan [mild (m): 3-6 mm, moderate
(M): 6-12 mm and severe (S). 12 mm] along with clinical character-
istics (age, sex, diagnosis, co-morbidities, type of transplant, condi-
tioning regimen and neutropenia length) were evaluated and
correlated with clinical outcomes [complicated (CNE) vs. non-
complicated (cNE)] andmortality. CNEwas defined as those who be-
came bacteremic with enteric flora, required ICU admission or died.
Results: 264 pts underwent a HSCT from 2004 to 2010. A total of
24 (9.1%) pts (average age 52.67 yrs, range 23 – 70yrs) were diag-
nosed with NE. 14 (58.3%) pts underwent an autologous HSCT
and 10 (41.7%) an allogeneic HSCT. Median BWT was 6 mm
(range 2 -15 mm). 11 (45.8%) pts had mBWT, 9 (37.5%) pts
MBWT and 3 (12.5%) pts SBWT. 13(54.2%) pts had cNE and 11
(45.2%) pts had CNE. 7(29.2%) pts required ICU admission and
3 (12.5%) pts died. Clinical characteristics had no impact onmorbid-
ity or mortality in our pt population. Degree of BWT failed to im-
pact mortality on univariate analysis (dead vs. alive: $ 3mm p 5
0.25, $ 6 mm p 5 0.48, $ 12 mm p 5 1.00), but the presence of
MBWT and SBWT ($ 6 mm) was associated with a higher rate
of CNE (CNE vs. cNE: $ 6 mm p 5 0.003 OR:30.0, 95 % CI2.6-342.7). BWT$ 6 mm highly correlated with CNE on multivar-
iate analysis (p 5 0.009 OR:31.5 [2.35-422.3]).
Conclusion: Clinical characteristics had no prognostic impact in
adult patients who developed neutropenic enterocolitis following
HSCT. Patients with moderate and severe bowel thickening have
a worse clinical outcome however this failed to predict mortality;
likely the result of a small sample size. Larger studies and develop-
ment of standardized criteria for bowel thickness measurement are
warranted.122
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In the 1990’s high-dose chemotherapy (HDCT) with autologous
hematopoietic cell transplantation (auto-HCT) was considered
a promising, potentially curative treatment approach for patients
(pts) with advanced or metastatic breast cancer (MBC). When ran-
domized trials did not confirm a significant benefit of HDCT over
standard chemotherapy (CTx) enthusiasm for this therapy fell and
transplantation studies ended abruptly. Despite improvements in
overall survival (OS) due to better CTx, endocrine, and immunologic
agents, MBC remains an incurable disease. One potential reason for
the failure ofHDCTwith auto-HCT is the high rate of occult tumor
cell contamination (OTC) in bone marrow, and accordingly in mo-
bilized blood grafts. Here we report the long-term follow-up of 15
pts that underwent HDCT (cisplatin, cyclophosphamide, BCNU)
at our institution between 12/96 and 4/98. FACS-purified
CD341Thy11 hematopoietic stem cells (HSC) with no detectable
tumor contamination (detection level 1/106 cells) were used as
grafts. Of note, 4/15 leukapheresis products contained OTC prior
to sorting. Pts were a median age of 43 years (y), were treated for pri-
mary stage IV BC (n5 5), or relapsed BC (n5 10). Status of remis-
sion at HCT was CR in 47%, and PR and SD in each 26.5% of pts.
More than 12 years after the end of the study 33% pts are alive, 27%
in CR. Median progression-free survival (PFS) is 16 months (m), the
PFS rate at 3y is 47%, at 10y 27%, each. Median OS for the entire
group and for survivors is 120m and 160m, respectively. 5y and
10y OS rates are 60% and 47%, respectively. In comparison, of 78
pts given the same HDCT regimen but unmanipulated grafts, 9%
are alive, and 6% without disease, 71% died of their BC, 22% died
of other reasons, and 4% were lost to follow-up. Median PFS is
9m, and the PFS rates at 3, 5, and 10y are 18%, 11%, and 8%, respec-
tively. Median OS for the entire group was 26m, and 154m for the 7
survivors. OS rates at 3y, 5y and 10y were 39%, 25%, and 13%, re-
spectively. Even though pts numbers in the HSC group are small,
and may include a highly selected population, our data suggest that
infusion of a hematopoietic graft, devoid of OTC, may be critical
to prolong time to relapse, and increase the proportion of CR. We
believe HDCT could regain relevance within multimodal treatment
approaches, as a good remission and avoidance of relapse due to
OTC in the graft could serve as a foundation for treatment with
novel biological and small molecule agents.123
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Bone marrow transplant (BMT) clinical trials generally feature
fixed randomization schedules determined before patient accrue-
ment. Bayesian adaptive designs based on in-trial treatment
